Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
ArriVent BioPharma, Inc. (AVBP) had Cash Flow from Financial Activities of $81.87M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-31.40M |
|
-- |
|
-- |
|
$33.62M |
|
$-33.62M |
|
$2.22M |
|
$-31.40M |
|
$-31.40M |
|
$-31.40M |
|
$-31.40M |
|
$-31.40M |
|
$-31.40M |
|
$-33.62M |
|
$-33.62M |
|
35.01M |
|
35.01M |
|
$-0.90 |
|
$-0.90 |
|
| Balance Sheet Financials | |
$250.15M |
|
-- |
|
$19.36M |
|
$269.51M |
|
$19.64M |
|
-- |
|
-- |
|
$19.64M |
|
$249.87M |
|
$249.87M |
|
$249.87M |
|
37.49M |
|
| Cash Flow Statement Financials | |
$-94.13M |
|
$50.73M |
|
|
Cash Flow from Financial Activities |
$81.87M |
$74.29M |
|
$112.77M |
|
$38.47M |
|
$5.58M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.74 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-94.13M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.57% |
|
-12.57% |
|
-11.65% |
|
-12.57% |
|
$6.67 |
|
$-2.69 |
|
$-2.69 |
|